Semper Paratus Acquisition (TVGN) Competitors $1.20 -0.04 (-3.23%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$1.20 0.00 (-0.08%) As of 07/7/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TVGN vs. MLYS, AVDL, PHVS, NRIX, ARDX, ORIC, PRAX, ZYME, LENZ, and CRMDShould you be buying Semper Paratus Acquisition stock or one of its competitors? The main competitors of Semper Paratus Acquisition include Mineralys Therapeutics (MLYS), Avadel Pharmaceuticals (AVDL), Pharvaris (PHVS), Nurix Therapeutics (NRIX), Ardelyx (ARDX), Oric Pharmaceuticals (ORIC), Praxis Precision Medicines (PRAX), Zymeworks (ZYME), LENZ Therapeutics (LENZ), and CorMedix (CRMD). These companies are all part of the "pharmaceutical products" industry. Semper Paratus Acquisition vs. Its Competitors Mineralys Therapeutics Avadel Pharmaceuticals Pharvaris Nurix Therapeutics Ardelyx Oric Pharmaceuticals Praxis Precision Medicines Zymeworks LENZ Therapeutics CorMedix Semper Paratus Acquisition (NASDAQ:TVGN) and Mineralys Therapeutics (NASDAQ:MLYS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, dividends and analyst recommendations. Does the media refer more to TVGN or MLYS? In the previous week, Mineralys Therapeutics had 2 more articles in the media than Semper Paratus Acquisition. MarketBeat recorded 4 mentions for Mineralys Therapeutics and 2 mentions for Semper Paratus Acquisition. Semper Paratus Acquisition's average media sentiment score of 0.62 beat Mineralys Therapeutics' score of 0.53 indicating that Semper Paratus Acquisition is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Semper Paratus Acquisition 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mineralys Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals have more ownership in TVGN or MLYS? 84.5% of Mineralys Therapeutics shares are owned by institutional investors. 73.2% of Semper Paratus Acquisition shares are owned by company insiders. Comparatively, 33.2% of Mineralys Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Do analysts recommend TVGN or MLYS? Semper Paratus Acquisition presently has a consensus price target of $10.00, indicating a potential upside of 733.33%. Mineralys Therapeutics has a consensus price target of $32.25, indicating a potential upside of 138.36%. Given Semper Paratus Acquisition's stronger consensus rating and higher possible upside, equities research analysts plainly believe Semper Paratus Acquisition is more favorable than Mineralys Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Semper Paratus Acquisition 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Mineralys Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Is TVGN or MLYS more profitable? Semper Paratus Acquisition's return on equity of 0.00% beat Mineralys Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Semper Paratus AcquisitionN/A N/A -934.56% Mineralys Therapeutics N/A -71.15%-65.71% Which has more risk and volatility, TVGN or MLYS? Semper Paratus Acquisition has a beta of -0.73, meaning that its share price is 173% less volatile than the S&P 500. Comparatively, Mineralys Therapeutics has a beta of -0.3, meaning that its share price is 130% less volatile than the S&P 500. Which has stronger valuation & earnings, TVGN or MLYS? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSemper Paratus AcquisitionN/AN/A-$13.73MN/AN/AMineralys TherapeuticsN/AN/A-$177.81M-$3.73-3.63 SummarySemper Paratus Acquisition beats Mineralys Therapeutics on 6 of the 11 factors compared between the two stocks. Get Semper Paratus Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for TVGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TVGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TVGN vs. The Competition Export to ExcelMetricSemper Paratus AcquisitionMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$228.03M$2.91B$5.52B$9.02BDividend YieldN/A2.44%5.24%4.08%P/E RatioN/A20.3027.1920.04Price / SalesN/A250.76395.22100.83Price / CashN/A41.7026.2128.59Price / Book-13.337.397.925.55Net Income-$13.73M-$55.04M$3.17B$248.49M7 Day Performance-1.64%2.51%1.79%4.87%1 Month Performance-16.08%-0.21%1.28%6.63%1 Year Performance71.92%3.41%33.32%20.38% Semper Paratus Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TVGNSemper Paratus Acquisition3.947 of 5 stars$1.20-3.2%$10.00+733.3%+71.4%$228.03MN/A0.003Positive NewsMLYSMineralys Therapeutics2.1338 of 5 stars$13.53-1.3%$32.25+138.4%+8.8%$893.55MN/A-3.6328AVDLAvadel Pharmaceuticals2.4318 of 5 stars$8.85-3.8%$18.17+105.3%-39.9%$890M$169.12M-32.7870PHVSPharvaris1.7441 of 5 stars$17.60+3.5%$36.20+105.7%+8.1%$888.93MN/A-5.8530Positive NewsGap UpNRIXNurix Therapeutics1.6053 of 5 stars$11.39-2.1%$30.18+164.9%-36.5%$887.38M$54.55M-4.07300Upcoming EarningsGap DownARDXArdelyx4.4252 of 5 stars$3.92+6.2%$10.89+177.8%-17.8%$882.85M$333.61M-17.8290ORICOric Pharmaceuticals4.2207 of 5 stars$10.15-1.6%$19.17+88.8%+38.5%$878.66MN/A-5.4380PRAXPraxis Precision Medicines2.9217 of 5 stars$42.05-2.2%$92.11+119.1%+15.8%$875.87M$8.55M-3.92110ZYMEZymeworks2.0486 of 5 stars$12.55+0.6%$21.00+67.3%+47.3%$867.63M$93.38M-8.37460LENZLENZ Therapeutics1.3238 of 5 stars$29.31-2.9%$46.60+59.0%+74.4%$849.45MN/A-16.56110CRMDCorMedix2.5634 of 5 stars$12.32-1.4%$17.14+39.1%+177.2%$847.81M$43.47M56.0030High Trading Volume Related Companies and Tools Related Companies Mineralys Therapeutics Competitors Avadel Pharmaceuticals Competitors Pharvaris Competitors Nurix Therapeutics Competitors Ardelyx Competitors Oric Pharmaceuticals Competitors Praxis Precision Medicines Competitors Zymeworks Competitors LENZ Therapeutics Competitors CorMedix Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TVGN) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredInstant Cash (in 4 clicks)Since 1973, Wall Street has quietly used a strange little pricing quirk to cash flow billions. Now, for the...Awesomely, LLC | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Semper Paratus Acquisition Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Semper Paratus Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
